Skip to main content
XERS logo

Xeris Biopharma Holdings, Inc.

XERSNASDAQHealthcareDrug Manufacturers - Specialty & Generic

$10.45Today:- (-)1Y +18.95%

As of Oct 27, 2026 close

Market cap
$1.81B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$5.25$11.42
Volume (live)
-
Avg. volume (3M)
3.08M

Xeris Biopharma Holdings (XERS) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Xeris Biopharma Holdings had a P/E ratio of 2351.09, debt-to-equity of 18.85 (up from -9.17), a current ratio of 2.19 (up from 1.67) and return on assets of 4.4% (up from -6.5%). A current ratio of 2.19 means current assets exceed current liabilities.

Xeris Biopharma Holdings Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income StatementBalance SheetCash FlowRatios
Scroll to see more
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio2351.09-----
Forward P/E64.50-----
P/S Ratio4.462.491.981.647.37-
P/B Ratio95.15-17.07-47.864.003.84-
Price/FCF46.63-----
Price/OCF45.50-----
Enterprise Value Ratios
EV/Revenue5.033.482.972.057.26-
EV/EBITDA39.63-----
EV/EBIT58.99-----
EV/FCF52.58-----
Profitability & Returns
Return on Equity (ROE)---324.20%-134.83%-190.28%-378.20%
Return on Assets (ROA)4.40%-6.51%-8.25%-15.78%-28.45%-38.01%
Return on Capital Employed (ROCE)9.10%-15.10%-19.40%-30.20%-46.80%-62.30%
Leverage & Solvency Ratios
Debt/Equity18.85-9.17-33.794.380.932.58
Debt/EBITDA5.73-----
Debt/FCF9.24-----
Liquidity Ratios
Current Ratio2.191.671.642.541.805.40
Quick Ratio1.481.111.172.081.524.99
Efficiency Ratios
Asset Turnover0.830.630.490.340.210.15
Inventory Turnover0.730.850.901.061.011.77
Yield & Distribution Ratios
Earnings Yield0.04%-10.85%-19.18%-52.34%-33.59%-
FCF Yield2.14%-7.49%-15.18%-57.18%-26.44%-
Buyback Yield-17.69%-6.61%-1.51%-71.62%-85.32%-63.32%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Xeris Biopharma Holdings Financial Ratios

What is Xeris Biopharma Holdings's P/E ratio?

Xeris Biopharma Holdings's P/E ratio was 2351.09 for fiscal 2025 (period ended Dec 31, 2025).

What is Xeris Biopharma Holdings's debt-to-equity ratio?

Xeris Biopharma Holdings's debt-to-equity ratio was 18.85 for fiscal 2025 (period ended Dec 31, 2025). It was -9.17 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition